Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
This is a prospective, multicenter, open label study, to evaluate the safety, tolerability and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or ocular hypertension. The subjects will be followed for approximately 7 months (one-month washout and 6 months follow-up after injected of the OTX-TIC implant).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ocular Therapeutix, Inc.
Petaluma, California, United States
Ocular Therapeutix, Inc.
Torrance, California, United States
Ocular Therapeutix, Inc
Roswell, Georgia, United States
Ocular Therapeutix, Inc.
Austin, Texas, United States
Ocular Therapeutix, Inc.
Racine, Wisconsin, United States
Start Date
April 25, 2018
Primary Completion Date
May 24, 2021
Completion Date
May 24, 2021
Last Updated
October 1, 2024
19
ACTUAL participants
OTX-TIC
DRUG
Lead Sponsor
Ocular Therapeutix, Inc.
NCT07396441
NCT07390890
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05902871